120
Participants
Start Date
July 20, 2017
Primary Completion Date
January 15, 2020
Study Completion Date
January 15, 2020
FRα peptide plus Adjuvant (GM-CSF)
Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
Adjuvant (GM-CSF) Alone
Intradermal injection 125 μg GM-CSF
Memorial Sloan Kettering Cancer Center, New York
Hematology/Oncology Lenox Hill Hospital, New York
Abington Memorial Hospital, Abington
Duke University Medical Center, Durham
Mayo Clinic Florida, Jacksonville
Mt. Sinai Comprehensive Cancer Center, Miami Beach
Florida Cancer Specialist, West Palm Beach
Moffitt Cancer Center, Tampa
UAB Gynecology Oncology, Birmingham
Tennessee Oncology/Sarah Cannon Research Institute, Nashville
Research Partners, Jackson
Mayo Clinic Rochester, Rochester
MidAmerica Division, Inc. c/o Research Medical Center, Kansas City
Mayo Clinic Cancer Center, Phoenix
University Of New Mexico Comprehensive Cancer Center, Albuquerque
Women's Cancer Research Foundation, Newport Beach
OHSU, Portland
The Stamford Hospital/Bennett Cancer Center, Stamford
Lead Sponsor
Marker Therapeutics, Inc.
INDUSTRY